KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Accuray (ARAY) Long-Term Debt Repayments (2016 - 2023)

Accuray posted quarterly Long-Term Debt Repayments of $2.9 million for Q1 2023, little changed on a QoQ basis from $2.9 million in Q3 2022.

Accuray (ARAY) has 7 years of Long-Term Debt Repayments data on file, last reported at $2.9 million in Q1 2023.

For the quarter ending Q1 2023, Long-Term Debt Repayments changed N/A year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2024 stood at $2.9 million (down 50.0% YoY), and the FY2025 full-year result was $68.5 million, up 1270.0% from the prior year.
Long-Term Debt Repayments for Q1 2023 stood at $2.9 million, roughly flat from $2.9 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $10.5 million in Q3 2020 and bottomed at $500000.0 in Q4 2020.
The 4-year median for Long-Term Debt Repayments is $2.9 million (2022), against an average of $5.4 million.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn	1.42 Bn
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn	1.00 Bn
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn	-
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn	-
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn	-
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn	-
10	Accuray	47,295.88	-38.49 Mn	25.29 Mn	-

Historic Data

Download Data 🔒

Date	Value
Mar 31, 2023	2.87 Mn
Mar 31, 2023	2.87 Mn
Sep 30, 2022	2.87 Mn
Sep 30, 2022	2.87 Mn
Mar 31, 2021	10.50 Mn
Mar 31, 2021	10.50 Mn
Dec 31, 2020	500,000.00
Dec 31, 2020	500,000.00
Sep 30, 2020	10.50 Mn
Sep 30, 2020	10.50 Mn
Mar 31, 2018	40.22 Mn
Mar 31, 2018	40.22 Mn
Sep 30, 2017	29.58 Mn
Sep 30, 2017	29.58 Mn
Jun 30, 2017	61.50 Mn
Jun 30, 2017	61.50 Mn
Mar 31, 2017	1.18 Mn
Mar 31, 2017	1.18 Mn
Dec 31, 2016	5.88 Mn
Dec 31, 2016	5.88 Mn
Sep 30, 2016	36.61 Mn
Sep 30, 2016	36.61 Mn
Jun 30, 2016	875,000.00
Jun 30, 2016	875,000.00